1061 — Essex Bio-Technology Income Statement
0.000.00%
- HK$2.49bn
- HK$2.12bn
- HK$1.67bn
- 89
- 72
- 96
- 98
Annual income statement for Essex Bio-Technology, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 978 | 1,638 | 1,318 | 1,737 | 1,670 |
Cost of Revenue | |||||
Gross Profit | 794 | 1,396 | 1,189 | 1,562 | 1,499 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 726 | 1,234 | 1,046 | 1,378 | 1,285 |
Operating Profit | 252 | 404 | 272 | 359 | 384 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 251 | 394 | 260 | 346 | 376 |
Provision for Income Taxes | |||||
Net Income After Taxes | 219 | 346 | 225 | 275 | 307 |
Net Income Before Extraordinary Items | |||||
Net Income | 219 | 346 | 225 | 275 | 307 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 225 | 350 | 229 | 279 | 310 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.383 | 0.582 | 0.439 | 0.479 | 0.507 |
Dividends per Share |